A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely to ...

The research shows that as long as essential genes remain intact, our genomes can tolerate significant structural changes, ...

KBC Group NV lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,047.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating human disease.

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, is a groundbreaking gene-editing technology that ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

First demonstration of single AAV muscle editing in non-human primates: NanoCas achieved in vivo editing efficiencies of up to 30% when targeting dystrophin in the skeletal muscle of cynomolgus ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...